Shopping Cart 0
Cart Subtotal
USD 0

Global CINV Existing and Pipeline Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3480

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5220

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6960
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).

Scope of the Report:

This report focuses on the CINV Existing and Pipeline Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for CINV Existing and Pipeline Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million USD in 2023, from xx million USD in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

GlaxoSmithKline

Helsinn

Heron Therapeutics

Merck

Tesaro

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Aloxi (palonosetron)

Zofran Generic (ondansetron)

Kytril Generic (granisetron)

Emend (aprepitant)

Akynzeo (netupitant-palonosetron)

SUSTOL (extended release granisetron injection)

Rolapitant

Market Segment by Applications, can be divided into

Hospitals

Specialty Clinics

Diagnostic Centers Therapeutics

Hospital Pharmacies

Drugstores

There are 15 Chapters to deeply display the global CINV Existing and Pipeline Drugs market.

Chapter 1, to describe CINV Existing and Pipeline Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of CINV Existing and Pipeline Drugs, with sales, revenue, and price of CINV Existing and Pipeline Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of CINV Existing and Pipeline Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, CINV Existing and Pipeline Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe CINV Existing and Pipeline Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

READ MORE

Table Of Content

Scope

Table of Contents

1 Market Overview

1.1 CINV Existing and Pipeline Drugs Introduction

1.2 Market Analysis by Type

1.2.1 Aloxi (palonosetron)

1.2.2 Zofran Generic (ondansetron)

1.2.3 Kytril Generic (granisetron)

1.2.4 Emend (aprepitant)

1.2.5 Akynzeo (netupitant-palonosetron)

1.2.6 SUSTOL (extended release granisetron injection)

1.2.7 Rolapitant

1.3 Market Analysis by Applications

1.3.1 Hospitals

1.3.2 Specialty Clinics

1.3.3 Diagnostic Centers Therapeutics

1.3.4 Hospital Pharmacies

1.3.5 Drugstores

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 GlaxoSmithKline

2.1.1 Business Overview

2.1.2 CINV Existing and Pipeline Drugs Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Helsinn

2.2.1 Business Overview

2.2.2 CINV Existing and Pipeline Drugs Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Heron Therapeutics

2.3.1 Business Overview

2.3.2 CINV Existing and Pipeline Drugs Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Merck

2.4.1 Business Overview

2.4.2 CINV Existing and Pipeline Drugs Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Tesaro

2.5.1 Business Overview

2.5.2 CINV Existing and Pipeline Drugs Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global CINV Existing and Pipeline Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Manufacturer (2016-2017)

3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2017

3.3.2 Top 6 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global CINV Existing and Pipeline Drugs Market Analysis by Regions

4.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Regions

4.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Regions (2013-2018)

4.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Regions (2013-2018)

4.2 North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

4.3 Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

4.5 South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

5 North America CINV Existing and Pipeline Drugs by Countries

5.1 North America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

5.1.1 North America CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

5.1.2 North America CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

5.2 United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

5.3 Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

5.4 Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6 Europe CINV Existing and Pipeline Drugs by Countries

6.1 Europe CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

6.1.1 Europe CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

6.1.2 Europe CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

6.2 Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6.3 UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6.4 France CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6.5 Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6.6 Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7 Asia-Pacific CINV Existing and Pipeline Drugs by Countries

7.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

7.2 China CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7.3 Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7.4 Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7.5 India CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7.6 Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

8 South America CINV Existing and Pipeline Drugs by Countries

8.1 South America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

8.1.1 South America CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

8.1.2 South America CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

8.2 Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

8.3 Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

8.4 Colombia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9 Middle East and Africa CINV Existing and Pipeline Drugs by Countries

9.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9.3 UAE CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9.4 Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9.5 Nigeria CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9.6 South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

10 Global CINV Existing and Pipeline Drugs Market Segment by Type

10.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Type (2013-2018)

10.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Type (2013-2018)

10.2 Aloxi (palonosetron) Sales Growth and Price

10.2.1 Global Aloxi (palonosetron) Sales Growth (2013-2018)

10.2.2 Global Aloxi (palonosetron) Price (2013-2018)

10.3 Zofran Generic (ondansetron) Sales Growth and Price

10.3.1 Global Zofran Generic (ondansetron) Sales Growth (2013-2018)

10.3.2 Global Zofran Generic (ondansetron) Price (2013-2018)

10.4 Kytril Generic (granisetron) Sales Growth and Price

10.4.1 Global Kytril Generic (granisetron) Sales Growth (2013-2018)

10.4.2 Global Kytril Generic (granisetron) Price (2013-2018)

10.5 Emend (aprepitant) Sales Growth and Price

10.5.1 Global Emend (aprepitant) Sales Growth (2013-2018)

10.5.2 Global Emend (aprepitant) Price (2013-2018)

10.6 Akynzeo (netupitant-palonosetron) Sales Growth and Price

10.6.1 Global Akynzeo (netupitant-palonosetron) Sales Growth (2013-2018)

10.6.2 Global Akynzeo (netupitant-palonosetron) Price (2013-2018)

10.7 SUSTOL (extended release granisetron injection) Sales Growth and Price

10.7.1 Global SUSTOL (extended release granisetron injection) Sales Growth (2013-2018)

10.7.2 Global SUSTOL (extended release granisetron injection) Price (2013-2018)

10.8 Rolapitant Sales Growth and Price

10.8.1 Global Rolapitant Sales Growth (2013-2018)

10.8.2 Global Rolapitant Price (2013-2018)

11 Global CINV Existing and Pipeline Drugs Market Segment by Application

11.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2013-2018)

11.2 Hospitals Sales Growth (2013-2018)

11.3 Specialty Clinics Sales Growth (2013-2018)

11.4 Diagnostic Centers Therapeutics Sales Growth (2013-2018)

11.5 Hospital Pharmacies Sales Growth (2013-2018)

11.6 Drugstores Sales Growth (2013-2018)

12 CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2023)

12.2 CINV Existing and Pipeline Drugs Market Forecast by Regions (2018-2023)

12.2.1 North America CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.2.2 Europe CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.2.3 Asia-Pacific CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.2.4 South America CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.2.5 Middle East and Africa CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.3 CINV Existing and Pipeline Drugs Market Forecast by Type (2018-2023)

12.3.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2018-2023)

12.3.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2018-2023)

12.4 CINV Existing and Pipeline Drugs Market Forecast by Application (2018-2023)

12.4.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2018-2023)

12.4.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source


List Of Table

List of Tables and Figures

Figure CINV Existing and Pipeline Drugs Picture

Table Product Specifications of CINV Existing and Pipeline Drugs

Figure Global Sales Market Share of CINV Existing and Pipeline Drugs by Types in 2017

Table CINV Existing and Pipeline Drugs Types for Major Manufacturers

Figure Aloxi (palonosetron) Picture

Figure Zofran Generic (ondansetron) Picture

Figure Kytril Generic (granisetron) Picture

Figure Emend (aprepitant) Picture

Figure Akynzeo (netupitant-palonosetron) Picture

Figure SUSTOL (extended release granisetron injection) Picture

Figure Rolapitant Picture

Figure CINV Existing and Pipeline Drugs Sales Market Share by Applications in 2017

Figure Hospitals Picture

Figure Specialty Clinics Picture

Figure Diagnostic Centers Therapeutics Picture

Figure Hospital Pharmacies Picture

Figure Drugstores Picture

Figure United States CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Canada CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Mexico CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Germany CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure France CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure UK CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Russia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Italy CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure China CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Japan CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Korea CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure India CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Southeast Asia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Brazil CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Egypt CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Saudi Arabia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure South Africa CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Nigeria CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Table GlaxoSmithKline Basic Information, Manufacturing Base and Competitors

Table GlaxoSmithKline CINV Existing and Pipeline Drugs Type and Applications

Table GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Helsinn Basic Information, Manufacturing Base and Competitors

Table Helsinn CINV Existing and Pipeline Drugs Type and Applications

Table Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Heron Therapeutics Basic Information, Manufacturing Base and Competitors

Table Heron Therapeutics CINV Existing and Pipeline Drugs Type and Applications

Table Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Merck Basic Information, Manufacturing Base and Competitors

Table Merck CINV Existing and Pipeline Drugs Type and Applications

Table Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Tesaro Basic Information, Manufacturing Base and Competitors

Table Tesaro CINV Existing and Pipeline Drugs Type and Applications

Table Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Global CINV Existing and Pipeline Drugs Sales by Manufacturer (2016-2017)

Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2016

Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2017

Table Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2016-2017)

Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2016

Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2017

Figure Top 3 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2017

Figure Top 6 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2017

Figure Global CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Global CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales by Regions (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales Market Share by Regions (2013-2018)

Table Global CINV Existing and Pipeline Drugs Revenue by Regions (2013-2018)

Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2013

Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2017

Figure North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure North America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table North America CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table North America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Figure North America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2013

Figure North America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017

Table North America CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Table North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018)

Figure North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2013

Figure North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017

Figure United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Europe CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table Europe CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table Europe CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Table Europe CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Figure Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2016

Figure Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017

Figure Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure France CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table Asia-Pacific CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Figure Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries 2017

Table Asia-Pacific CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Figure Asia-Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Countries 2017

Figure China CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure India CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure South America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table South America CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table South America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Figure South America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017

Table South America CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Table South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018)

Figure South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017

Figure Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Colombia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table Middle East and Africa CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017

Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2013

Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017

Figure Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure UAE CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Nigeria CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales by Type (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales Share by Type (2013-2018)

Table Global CINV Existing and Pipeline Drugs Revenue by Type (2013-2018)

Table Global CINV Existing and Pipeline Drugs Revenue Share by Type (2013-2018)

Figure Global Aloxi (palonosetron) Sales Growth (2013-2018)

Figure Global Aloxi (palonosetron) Price (2013-2018)

Figure Global Zofran Generic (ondansetron) Sales Growth (2013-2018)

Figure Global Zofran Generic (ondansetron) Price (2013-2018)

Figure Global Kytril Generic (granisetron) Sales Growth (2013-2018)

Figure Global Kytril Generic (granisetron) Price (2013-2018)

Figure Global Emend (aprepitant) Sales Growth (2013-2018)

Figure Global Emend (aprepitant) Price (2013-2018)

Figure Global Akynzeo (netupitant-palonosetron) Sales Growth (2013-2018)

Figure Global Akynzeo (netupitant-palonosetron) Price (2013-2018)

Figure Global SUSTOL (extended release granisetron injection) Sales Growth (2013-2018)

Figure Global SUSTOL (extended release granisetron injection) Price (2013-2018)

Figure Global Rolapitant Sales Growth (2013-2018)

Figure Global Rolapitant Price (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales by Application (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales Share by Application (2013-2018)

Figure Global Specialty Clinics Sales Growth (2013-2018)

Figure Global Diagnostic Centers Therapeutics Sales Growth (2013-2018)

Figure Global Hospital Pharmacies Sales Growth (2013-2018)

Figure Global Drugstores Sales Growth (2013-2018)

Figure Global CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2023)

Table Global CINV Existing and Pipeline Drugs Sales Forecast by Regions (2018-2023)

Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Regions (2018-2023)

Figure North America Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Figure Europe Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Figure Asia-Pacific Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Figure South America Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Figure Middle East and Africa Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Table Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2018-2023)

Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2018-2023)

Table Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2018-2023)

Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2018-2023)

Table Distributors/Traders/ Dealers List

Licence Rights

Single User License - This is a single user license, allowing one specific user access to the product. The report will be emailed to you. The report is sent in PDF format.

Multi User License- allowing 1-20 people access to the product. The report will be emailed to you. The report is sent in PDF format and Excel Data. What's more, the comany can use the data, table, picture and figure on the report.

Corporate User License- This license will allow the entire company (Interface) to access the unlocked PDF version of this report without any restrictions. You can also take the print out if you wish toreceive the hard copy version of this report.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

GlaxoSmithKline

Helsinn

Heron Therapeutics

Merck

Tesaro

Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).

Scope of the Report:

This report focuses on the CINV Existing and Pipeline Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for CINV Existing and Pipeline Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million USD in 2023, from xx million USD in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

GlaxoSmithKline

Helsinn

Heron Therapeutics

Merck

Tesaro

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Aloxi (palonosetron)

Zofran Generic (ondansetron)

Kytril Generic (granisetron)

Emend (aprepitant)

Akynzeo (netupitant-palonosetron)

SUSTOL (extended release granisetron injection)

Rolapitant

Market Segment by Applications, can be divided into

Hospitals

Specialty Clinics

Diagnostic Centers Therapeutics

Hospital Pharmacies

Drugstores

There are 15 Chapters to deeply display the global CINV Existing and Pipeline Drugs market.

Chapter 1, to describe CINV Existing and Pipeline Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of CINV Existing and Pipeline Drugs, with sales, revenue, and price of CINV Existing and Pipeline Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of CINV Existing and Pipeline Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, CINV Existing and Pipeline Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe CINV Existing and Pipeline Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

READ MORE

Scope

Table of Contents

1 Market Overview

1.1 CINV Existing and Pipeline Drugs Introduction

1.2 Market Analysis by Type

1.2.1 Aloxi (palonosetron)

1.2.2 Zofran Generic (ondansetron)

1.2.3 Kytril Generic (granisetron)

1.2.4 Emend (aprepitant)

1.2.5 Akynzeo (netupitant-palonosetron)

1.2.6 SUSTOL (extended release granisetron injection)

1.2.7 Rolapitant

1.3 Market Analysis by Applications

1.3.1 Hospitals

1.3.2 Specialty Clinics

1.3.3 Diagnostic Centers Therapeutics

1.3.4 Hospital Pharmacies

1.3.5 Drugstores

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 GlaxoSmithKline

2.1.1 Business Overview

2.1.2 CINV Existing and Pipeline Drugs Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Helsinn

2.2.1 Business Overview

2.2.2 CINV Existing and Pipeline Drugs Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Heron Therapeutics

2.3.1 Business Overview

2.3.2 CINV Existing and Pipeline Drugs Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Merck

2.4.1 Business Overview

2.4.2 CINV Existing and Pipeline Drugs Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Tesaro

2.5.1 Business Overview

2.5.2 CINV Existing and Pipeline Drugs Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global CINV Existing and Pipeline Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Manufacturer (2016-2017)

3.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2017

3.3.2 Top 6 CINV Existing and Pipeline Drugs Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global CINV Existing and Pipeline Drugs Market Analysis by Regions

4.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Regions

4.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Regions (2013-2018)

4.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Regions (2013-2018)

4.2 North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

4.3 Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

4.5 South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

5 North America CINV Existing and Pipeline Drugs by Countries

5.1 North America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

5.1.1 North America CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

5.1.2 North America CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

5.2 United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

5.3 Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

5.4 Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6 Europe CINV Existing and Pipeline Drugs by Countries

6.1 Europe CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

6.1.1 Europe CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

6.1.2 Europe CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

6.2 Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6.3 UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6.4 France CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6.5 Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

6.6 Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7 Asia-Pacific CINV Existing and Pipeline Drugs by Countries

7.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

7.2 China CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7.3 Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7.4 Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7.5 India CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

7.6 Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

8 South America CINV Existing and Pipeline Drugs by Countries

8.1 South America CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

8.1.1 South America CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

8.1.2 South America CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

8.2 Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

8.3 Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

8.4 Colombia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9 Middle East and Africa CINV Existing and Pipeline Drugs by Countries

9.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9.3 UAE CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9.4 Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9.5 Nigeria CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

9.6 South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

10 Global CINV Existing and Pipeline Drugs Market Segment by Type

10.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global CINV Existing and Pipeline Drugs Sales and Market Share by Type (2013-2018)

10.1.2 Global CINV Existing and Pipeline Drugs Revenue and Market Share by Type (2013-2018)

10.2 Aloxi (palonosetron) Sales Growth and Price

10.2.1 Global Aloxi (palonosetron) Sales Growth (2013-2018)

10.2.2 Global Aloxi (palonosetron) Price (2013-2018)

10.3 Zofran Generic (ondansetron) Sales Growth and Price

10.3.1 Global Zofran Generic (ondansetron) Sales Growth (2013-2018)

10.3.2 Global Zofran Generic (ondansetron) Price (2013-2018)

10.4 Kytril Generic (granisetron) Sales Growth and Price

10.4.1 Global Kytril Generic (granisetron) Sales Growth (2013-2018)

10.4.2 Global Kytril Generic (granisetron) Price (2013-2018)

10.5 Emend (aprepitant) Sales Growth and Price

10.5.1 Global Emend (aprepitant) Sales Growth (2013-2018)

10.5.2 Global Emend (aprepitant) Price (2013-2018)

10.6 Akynzeo (netupitant-palonosetron) Sales Growth and Price

10.6.1 Global Akynzeo (netupitant-palonosetron) Sales Growth (2013-2018)

10.6.2 Global Akynzeo (netupitant-palonosetron) Price (2013-2018)

10.7 SUSTOL (extended release granisetron injection) Sales Growth and Price

10.7.1 Global SUSTOL (extended release granisetron injection) Sales Growth (2013-2018)

10.7.2 Global SUSTOL (extended release granisetron injection) Price (2013-2018)

10.8 Rolapitant Sales Growth and Price

10.8.1 Global Rolapitant Sales Growth (2013-2018)

10.8.2 Global Rolapitant Price (2013-2018)

11 Global CINV Existing and Pipeline Drugs Market Segment by Application

11.1 Global CINV Existing and Pipeline Drugs Sales Market Share by Application (2013-2018)

11.2 Hospitals Sales Growth (2013-2018)

11.3 Specialty Clinics Sales Growth (2013-2018)

11.4 Diagnostic Centers Therapeutics Sales Growth (2013-2018)

11.5 Hospital Pharmacies Sales Growth (2013-2018)

11.6 Drugstores Sales Growth (2013-2018)

12 CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.1 Global CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2023)

12.2 CINV Existing and Pipeline Drugs Market Forecast by Regions (2018-2023)

12.2.1 North America CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.2.2 Europe CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.2.3 Asia-Pacific CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.2.4 South America CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.2.5 Middle East and Africa CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

12.3 CINV Existing and Pipeline Drugs Market Forecast by Type (2018-2023)

12.3.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2018-2023)

12.3.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2018-2023)

12.4 CINV Existing and Pipeline Drugs Market Forecast by Application (2018-2023)

12.4.1 Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2018-2023)

12.4.2 Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source


List Of Table

List of Tables and Figures

Figure CINV Existing and Pipeline Drugs Picture

Table Product Specifications of CINV Existing and Pipeline Drugs

Figure Global Sales Market Share of CINV Existing and Pipeline Drugs by Types in 2017

Table CINV Existing and Pipeline Drugs Types for Major Manufacturers

Figure Aloxi (palonosetron) Picture

Figure Zofran Generic (ondansetron) Picture

Figure Kytril Generic (granisetron) Picture

Figure Emend (aprepitant) Picture

Figure Akynzeo (netupitant-palonosetron) Picture

Figure SUSTOL (extended release granisetron injection) Picture

Figure Rolapitant Picture

Figure CINV Existing and Pipeline Drugs Sales Market Share by Applications in 2017

Figure Hospitals Picture

Figure Specialty Clinics Picture

Figure Diagnostic Centers Therapeutics Picture

Figure Hospital Pharmacies Picture

Figure Drugstores Picture

Figure United States CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Canada CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Mexico CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Germany CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure France CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure UK CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Russia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Italy CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure China CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Japan CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Korea CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure India CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Southeast Asia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Brazil CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Egypt CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Saudi Arabia CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure South Africa CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Figure Nigeria CINV Existing and Pipeline Drugs Revenue (Value) and Growth Rate (2013-2023)

Table GlaxoSmithKline Basic Information, Manufacturing Base and Competitors

Table GlaxoSmithKline CINV Existing and Pipeline Drugs Type and Applications

Table GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Helsinn Basic Information, Manufacturing Base and Competitors

Table Helsinn CINV Existing and Pipeline Drugs Type and Applications

Table Helsinn CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Heron Therapeutics Basic Information, Manufacturing Base and Competitors

Table Heron Therapeutics CINV Existing and Pipeline Drugs Type and Applications

Table Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Merck Basic Information, Manufacturing Base and Competitors

Table Merck CINV Existing and Pipeline Drugs Type and Applications

Table Merck CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Tesaro Basic Information, Manufacturing Base and Competitors

Table Tesaro CINV Existing and Pipeline Drugs Type and Applications

Table Tesaro CINV Existing and Pipeline Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

Table Global CINV Existing and Pipeline Drugs Sales by Manufacturer (2016-2017)

Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2016

Figure Global CINV Existing and Pipeline Drugs Sales Market Share by Manufacturer in 2017

Table Global CINV Existing and Pipeline Drugs Revenue by Manufacturer (2016-2017)

Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2016

Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Manufacturer in 2017

Figure Top 3 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2017

Figure Top 6 CINV Existing and Pipeline Drugs Manufacturer (Revenue) Market Share in 2017

Figure Global CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Global CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales by Regions (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales Market Share by Regions (2013-2018)

Table Global CINV Existing and Pipeline Drugs Revenue by Regions (2013-2018)

Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2013

Figure Global CINV Existing and Pipeline Drugs Revenue Market Share by Regions in 2017

Figure North America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Europe CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Asia-Pacific CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure South America CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure North America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table North America CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table North America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Figure North America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2013

Figure North America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017

Table North America CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Table North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018)

Figure North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2013

Figure North America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017

Figure United States CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Canada CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Mexico CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Europe CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table Europe CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table Europe CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Table Europe CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Figure Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2016

Figure Europe CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017

Figure Germany CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure UK CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure France CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Russia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Italy CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Asia-Pacific CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table Asia-Pacific CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Figure Asia-Pacific CINV Existing and Pipeline Drugs Sales Market Share by Countries 2017

Table Asia-Pacific CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Figure Asia-Pacific CINV Existing and Pipeline Drugs Revenue Market Share by Countries 2017

Figure China CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Japan CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Korea CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure India CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Southeast Asia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure South America CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table South America CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table South America CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Figure South America CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017

Table South America CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Table South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018)

Figure South America CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017

Figure Brazil CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Argentina CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Colombia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue and Growth Rate (2013-2018)

Table Middle East and Africa CINV Existing and Pipeline Drugs Sales by Countries (2013-2018)

Table Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries (2013-2018)

Figure Middle East and Africa CINV Existing and Pipeline Drugs Sales Market Share by Countries in 2017

Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue by Countries (2013-2018)

Table Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries (2013-2018)

Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2013

Figure Middle East and Africa CINV Existing and Pipeline Drugs Revenue Market Share by Countries in 2017

Figure Saudi Arabia CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure UAE CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Egypt CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure Nigeria CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Figure South Africa CINV Existing and Pipeline Drugs Sales and Growth Rate (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales by Type (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales Share by Type (2013-2018)

Table Global CINV Existing and Pipeline Drugs Revenue by Type (2013-2018)

Table Global CINV Existing and Pipeline Drugs Revenue Share by Type (2013-2018)

Figure Global Aloxi (palonosetron) Sales Growth (2013-2018)

Figure Global Aloxi (palonosetron) Price (2013-2018)

Figure Global Zofran Generic (ondansetron) Sales Growth (2013-2018)

Figure Global Zofran Generic (ondansetron) Price (2013-2018)

Figure Global Kytril Generic (granisetron) Sales Growth (2013-2018)

Figure Global Kytril Generic (granisetron) Price (2013-2018)

Figure Global Emend (aprepitant) Sales Growth (2013-2018)

Figure Global Emend (aprepitant) Price (2013-2018)

Figure Global Akynzeo (netupitant-palonosetron) Sales Growth (2013-2018)

Figure Global Akynzeo (netupitant-palonosetron) Price (2013-2018)

Figure Global SUSTOL (extended release granisetron injection) Sales Growth (2013-2018)

Figure Global SUSTOL (extended release granisetron injection) Price (2013-2018)

Figure Global Rolapitant Sales Growth (2013-2018)

Figure Global Rolapitant Price (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales by Application (2013-2018)

Table Global CINV Existing and Pipeline Drugs Sales Share by Application (2013-2018)

Figure Global Specialty Clinics Sales Growth (2013-2018)

Figure Global Diagnostic Centers Therapeutics Sales Growth (2013-2018)

Figure Global Hospital Pharmacies Sales Growth (2013-2018)

Figure Global Drugstores Sales Growth (2013-2018)

Figure Global CINV Existing and Pipeline Drugs Sales, Revenue and Growth Rate (2018-2023)

Table Global CINV Existing and Pipeline Drugs Sales Forecast by Regions (2018-2023)

Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Regions (2018-2023)

Figure North America Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Figure Europe Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Figure Asia-Pacific Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Figure South America Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Figure Middle East and Africa Sales CINV Existing and Pipeline Drugs Market Forecast (2018-2023)

Table Global CINV Existing and Pipeline Drugs Sales Forecast by Type (2018-2023)

Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Type (2018-2023)

Table Global CINV Existing and Pipeline Drugs Sales Forecast by Application (2018-2023)

Table Global CINV Existing and Pipeline Drugs Market Share Forecast by Application (2018-2023)

Table Distributors/Traders/ Dealers List

Single User License - This is a single user license, allowing one specific user access to the product. The report will be emailed to you. The report is sent in PDF format.

Multi User License- allowing 1-20 people access to the product. The report will be emailed to you. The report is sent in PDF format and Excel Data. What's more, the comany can use the data, table, picture and figure on the report.

Corporate User License- This license will allow the entire company (Interface) to access the unlocked PDF version of this report without any restrictions. You can also take the print out if you wish toreceive the hard copy version of this report.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

GlaxoSmithKline

Helsinn

Heron Therapeutics

Merck

Tesaro